Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure

@article{HosseiniZare2012PeripheralNR,
  title={Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure},
  author={Mahshid S Hosseini-Zare and Simin Dashti-Khavidaki and Mitra Mahdavi-Mazdeh and Farrokhlegha Ahmadi and Shahram Akrami},
  journal={Clinical Neurology and Neurosurgery},
  year={2012},
  volume={114},
  pages={663-667}
}
View on Elsevier
doi.org
11 Citations
Background Citations
1
Results Citations
2

11 Citations

Effect of Erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study

The use of ESA may improve uremic neuropathy in patients with newly diagnosed ESKD who have been started on hemodialysis, and patients in group A showed improvement of some electrophysiological features.

Recombinant Human Erythropoietin Restrains Oxidative Stress in Streptozotocin-induced Diabetic Rats Exposed to Renal Ischemia Reperfusion Injury.

Electrophysiological measurements of diabetic peripheral neuropathy: A systematic review.

The importance of association between angiotensin-converting enzyme (ACE) Gene I/D polymorphism and diabetic peripheral neuropathy.

Age-associated changes in vascular health and its relation with erythropoietin

It is concluded that ageing influences PWV, ASI, MAP and EPO in men and women participants.

Influence Of Oxidative Stress On Erythrocyte’s Formation And Function Resulting In Anemia

This review provides insight into the mechanism followed by oxidative stress to reduce the amounts of erythrocytes in the body resulting in the development of anemia.

Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin‐induced diabetic rats

Although erythropoietin was demonstrated to have neuroprotective effects in neurodegenerative diseases, the effects of EPO on glucose‐evoked oxidative stress and apoptosis of SCs remain unknown.

DEVELOPMENT OF PROTEIN DRUGS

This review highlights the emerging trends and approaches in protein drug development by using examples of therapeutic proteins approved by the U.S. Food and Drug Administration over the previous five years (2011–2016, namely January 1, 2011, through August 31, 2016).

Neuroprotective Effects of Concomitant Use of Erythropoietin and Progesterone in Traumatic Brain Injury

The next generation of scientists will have to think more strategically about how to combine big data and big data analytics in the coming generation of smartphones.

Síndrome de dolor regional complejo asociado a terapia con eritropoyetina

References

SHOWING 1-10 OF 36 REFERENCES

Effect of erythropoietin therapy on polyneuropathy in predialytic patients.

Subcutaneous EPO therapy improved motor polyneuropathy in uremic patients, especially non-diabetic individuals, and this non-hematopoietic effect may be related to some direct action through EPO receptors on peripheral neurons.

Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure.

Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.

Anemia associated with EPO deficiency can occur early in DN before the onset of advanced renal failure, but does not normally occur in nondiabetic renal disease of similar severity.

Accelerated neuropathy of renal failure.

This partly reversible acute uremic neuropathy, which is probably caused by the metabolic disturbances of end-stage renal failure, simulates Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy and may be complicated by diabetic neuropathy.

Peripheral neuropathies associated with chronic renal failure.

  • C. Bolton
  • Medicine, Biology
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 1980
While chronic hemodialysis stabilizes uremic neuropathy, manipulation of he modialysis schedules may not alter its course, according to current assessment.

Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus

Inappropriately low serum Epo level is a uniform feature in patients with type II diabetes mellitus and may represent a constitutive blunted response to anemia or an altered metabolic rate of Epo, probably as a result of abnormal glycosylation of the cytokine.

Utility of dorsal sural nerve in early determination of diabetic polyneuropathy

The value of dorsal sural nerve to diagnose early polyneuropathy in diabetic patients with normal routine nerve conduction studies is reported, and no statistically significant difference was found for conduction velocities and distal latencies of sural nerves between the diabetic patients and the controls.

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.

Nerve biopsy and conduction studies in diabetic neuropathy.

Morphological findings in sural nerves were related to nerve conduction in 12 patients with diabetic neuropathy, five with mainly sensory involvement, four with severe, symmetrical sensory-motor…

The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus.